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Background: Aerosol delivery is a cornerstone of CF airways disease management. New nebulisers have reduced treatment times by utilising
mesh technology for aerosol production. We have evaluated a further modification (target inhalation mode (TIM)) that may reduce treatment
delivery times further.
Methods: Following a baseline period on tidal breathing mode (TBM), children with CF on long-term aerosol therapy were randomly allocated to
either TIM, which optimises patient inhalations through a direct feedback mechanism, or to continue TBM. The primary outcome was nebuliser
treatment times with secondary outcomes being adherence and patient preference.
Results: The ten children allocated TIM reduced their mean (SD) treatment times from 6.9(2.9) to 3.7(2.3) minutes (pb0.001). In contrast,
treatment times were unchanged in the ten children allocated TBM. Mean adherence was maintained in the TIM group but declined in patients
allocated TBM by N5%. All children preferred TIM to TBM.
Conclusion: TIM reduces nebuliser treatment times and may positively impact on adherence, although longer duration studies are required to
examine this.
(ISRCTN65617839)
© 2011 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.1. Introduction
Topical delivery of aerosolised therapies is an established
treatment for chronic airway infection and inflammation in
cystic fibrosis (CF).[1] Most drugs are delivered in an
aerosolised form through a nebuliser and include antibiotics,
Dornase alpha and hypertonic saline.[2,3] Recent innovations
in nebuliser technology have resulted in improved delivery
times and better airway deposition.[4] An additional feature
of these new devices is the ability to record and examine the☆ Previous presentations: Some of these data were presented in a symposium at th
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doi:10.1016/j.jcf.2011.04.006performance of the device by downloading stored data
(electronic data capture).[5] In this way, CF teams are able
to work with patients to optimise performance and support
adherence.[5] The development of mesh technology facili-
tated the production of fine particle aerosols and realised the
potential for adaptive aerosol delivery (AAD).[6] The concept
of AAD is to time aerosol delivery with a certain phase of the
respiratory cycle, by monitoring flow in and out of the
mouthpiece. For the I-neb™AAD device, a pulse of aerosol is
generated during the mid/late phase of inspiration with a onee European Cystic Fibrosis Conference in June 2010 in Valencia, Spain.
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deposition.[7] A recent innovation for the I-neb AAD device
has been Target Inhalation Mode (TIM). [8] This provides
direct feedback to the patient (through a vibrating mouthpiece),
which encourages the patient to maximise inspiration. Radio-
labelled aerosol studies have demonstrated improved lung
deposition with TIM compared to standard tidal breathing mode
(TBM).[9,10].
In this study, we have undertaken a randomised controlled
trial to evaluate the impact of TIM compared to TBM on
treatment times in a paediatric population. Treatment times
and adherence were measured by electronic data capture.2. Methods
2.1. Study design
This study was a randomised controlled trial comparing
target inhalation mode (TIM) with standard tidal breathing
mode (TBM) (ISRCTN65617839). The protocol was designed
following CONSORT guidance.[11] The adaptive aerosol
delivery (AAD) device was the I-neb™ (Respironics, Philips,
Chichester, UK). After a baseline period of 4–6 weeks on TBM,
patients were randomised to TIM or to continue TBM for 8–
10 weeks (Appendix A). Computer generation of treatment
allocation was by an independent researcher (not involved in the
study) and concealed in opaque envelopes. A research
physiotherapist (PMcC) undertook treatment allocation,
instructed patients on the use of TIM and downloaded data. A
researcher blinded to treatment allocation (PMcN) performed
the data analysis. The primary outcome measure was average
time for each treatment episode, calculated from data download.
Secondary outcomes included treatment adherence (calculated
as a percentage of expected treatments) and a patient preference
questionnaire. Pulmonary function, adverse events and with-
drawals were also recorded.2.2. Participants
Clinically stable CF patients (5–16 years) attending the
regional CF clinic at Alder Hey Children's Hospital were
invited to participate in the study at their regular clinic visit.
Inclusion criteria comprised all patients with Pseudomonas
aeruginosa infection who were established on long-term
(N3 months) antibiotic therapy through the I-nebTM using
standard tidal breathing mode (TBM) of inhalation.
Patients with a pulmonary exacerbation in the previous four
weeks were excluded. Pulmonary exacerbations were defined as
an increase in cough, sputum production and/or a reduction in
Forced Expiratory Volume in one second (FEV1) greater than
10% of the previously recorded value.
At enrolment, patient demographics and clinical character-
istics including their clinical status, most recent sputum/cough
swab microbiology and annual review results (including
pulmonary function tests, Northern Chest X-ray Score, and
Schwachman score) were documented.2.3. Patient preference questionnaire
At the final study visit patients randomised to TIM were
asked to fill in a patient preference questionnaire. With the
help of their parents they were asked to rate the answer from
“completely agree” to “completely disagree” (Appendix B).
2.4. Treatment regimens
Treatment regimens were not changed during the study
period (including the baseline). A commercial preparation of
colistin was used (Promixin®, Profile Pharma Ltd., Chichester,
UK) with a standard treatment dose being 1 MU (mega unit)
diluted in 2 ml normal saline (1 ml being used for each of two
daily treatments). In some patients, a once daily dose of 1 MU
colistin in 1 ml normal saline was prescribed. Dornase alfa
(Pulmozyme®) was also prescribed in several patients once
daily.
2.5. Breathing modes for the AAD device
2.5.1. Tidal breathing mode (standard technique)
Tidal breathing mode delivers aerosol particles of medi-
cation during normal tidal breathing. The I-neb™ monitors
and analyses the patient's first three breaths to determine
breathing pattern and then delivers a timed pulse of aerosol
during the mid-phase of the next inspiration. Throughout the
treatment, each pulsed delivery of aerosol continues to be
based on the breathing pattern of the preceding three breaths.
The device calculates the volume of each inhalation and once
the pre-programmed total dose of drug is delivered, gives
audio and visual feedback informing the patient that treatment
is complete. This is the standard method of drug delivery for
the I-neb™.
2.5.2. Target inhalation mode (proposed intervention)
A high resistance mouthpiece guides the patient to use
slower and deeper inhalations. The patient is encouraged to
lengthen each inhalation by a vibratory feedback on the lip,
which is the signal to exhale. Target inhalation mode guides the
patient into taking the longest inhalation they can manage by
gradually increasing the time from the beginning of each breath
to the vibration. Once the maximum length of inhalation has
been found (i.e. when the patient is unable to reach the
vibration), the time is then shortened to a comfortable level for
the patient and remains at this level until the preset dose is
achieved. Visual and audio feedback will inform the patient
that treatment is complete.
2.6. Data download
Electronic data capture was undertaken at each study visit
using a docking station for the I-neb™ device and software
provided by the company (Insight system software, Philips,
Chichester, UK). Device performance was assessed at
enrolment and new equipment provided for all patients
(mesh plate and mouth piece). A training programme within
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breathing technique for each patient. Data were downloaded at
each study visit (end of baseline/randomisation, visit 2 and
end of study, visit 3). At the end of the study, patients
allocated TBM were offered TIM. Percentage adherence was
defined as the number of treatments taken/number of
prescribed treatments x100.
2.7. Data analysis
Data were analysed using both paired-samples T test (for within
patient comparisons) and Independent-samples T test (for relative
change in outcomes over the study period between groups). We
used SPSS 17.01 and all statistical tests were two-tailed with a p
value equal to or less than 0.05 considered statistically significant.
Sample size was informed by the standard deviation of treatment
time in a previous study,[5] incorporating guidance on the design of
a pilot explanatory study.[12].
2.8. Ethics
Study was approved by Alder Hey Children's NHS
Foundation Trust Research Review Committee and the National
Research Ethics Committee.
3. Results
Recruitment to the study was from July 2009 to April
2010. Twenty children were assessed for eligibility and
allocated an intervention. None were excluded or lost to
follow-up.
3.1. Patient characteristics
10 patients (7 male) were randomised to TIM and 10 (7)
continued on TBM. All patients completed the study and data
were analysed on an intention to treat basis (Appendix C).
The patients were prescribed 1–3 treatments a day.
Pseudomonas aeruginosa was isolated from 7 patients in each
group during their study participation. Baseline characteristicsTable 1
Patient characteristics at baseline.
Gender: male / female
Median (range) Age (years)
Median (range) FEV1 (% predicted)
Median (range) FEV1 litres/min
Median (range) FVC (% predicted)
Median (range) FVC litres/min
Median (range) Schwachman score
Median (range) CXR score
Median (range) number of treatments/day
Mean (SD) duration (months) of AAD TBM therapy prior to studybetween the two groups were similar (Table 1). Average (SD)
duration of the baseline period was 6 (2.2) weeks and for the
intervention period, 8.3 (2.2) weeks.
One patient, in the TIM group, had an intermittent fault
identified with his base unit and this was replaced during the
course of the study.
3.2. Outcome measures
Mean (SD) treatment times were not significantly different
between the two groups at baseline (TBM, 6.9 (3.0); TIM 6.9
(2.9) minutes). Patients allocated TIM had a significant
reduction in treatment time to 3.7 (2.3) minutes (pb0.001)
over the study period, whereas treatment times in the TBM
group were maintained (7.3 (3.2) minutes) (Fig. 1).
Mean (SD) adherence was not significantly different
between the two groups at baseline (TBM, 72(30)%: TIM, 86
(11)), although 2 patients in the TBM group had adherence in
the poor range (b40%). Adherence at the end of the study in
TIM and TBM groups were 89 (8) and 65 (33)% respectively
(Fig. 2). Thus, adherence was maintained in the TIM group but
declined in patients allocated TBM by N5%.
There were no changes in lung function or any other clinical
parameter between the two groups. Low FVC measurements
did not prevent any patient from using TIM.
3.3. Patient preference questionnaire
100% patients completely agreed or agreed with the
statement that 1) TIM was very easy to understand, 2) very
easy to use and 3) they were able to use it straight away. All
patients randomised to TIM preferred its use to TBM aerosol
delivery. There were no adverse events or patient
withdrawals.
4. Discussion
For children with CF the use of target inhalation mode
resulted in a reduction in the average time to complete a
nebulised treatment during this study period of 8 weeks.TIM TBM
7 / 3 7 / 3
11.7 (8.7–15.9) 10.6 (5.2–16.9)
74 (60–105) 80 (53–100)
1.8 (1.2–3.9) 1.8 (1.1–3.0)
94 (59–107) 89 (54–109)
2.2 (1.7–4.7) 2.2 (1.3–4.3)
85/100 (65–95) 88/100 (60–100)
4/20 (2–9) 4/20 (1–12)
2(1–3) 2(1–2)
42.2(10.4) 34.7(12.5)
Fig. 1. a) Line graph showing individual changes in treatment times (minutes) for patients in TBM and TIM groups. Paired treatment times significantly decreased
between the start and the end of the study period for patients allocated TIM but not TBM. b) Boxplot showing change in treatment times over the study period.
Treatment times decreased in the TIM group by over 2 min but remained the same in patients allocated TBM (pb0.0001).
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declined in patients using the standard TBM. There was no
difference in lung function between the two groups. PatientsFig. 2. a) Line graph showing individual changes in adherence (%) for patients in T
the baseline period between the two groups, despite the two poorly adherent patie
(%) following randomisation to TBM or TIM. Adherence declined in patients a
(*p=0.012).randomized to TIM preferred this mode to TBM and all
patients opted to continue with TIM after the study period.
These results support preliminary data examining singleBM and TIM groups. Overall, adherence was not significantly different during
nts in the TBM group. b) Boxplot (with outlier) showing change in adherence
llocated TBM by approximately 5% but was maintained in the TIM group
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with previous open assessments of this strategy, which are
reassuring with respect to lung deposition.[9,10,13].
We expected TIM to have an impact on average treatment
time, however the extent of this reduction was more than
anticipated. We suspected that younger patients may find the
technique of generating prolonged inspirations a challenge.
Evidently, this was not the case and in most the reduction in
treatment time was impressive. The reduction was marked in
three patients but consistent across the group, in contrast to the
TBM group (Fig. 1). We did not anticipate a difference in
treatment adherence given the short study period and the fact
that all children were established on their nebuliser regimen
before entry into the study. This was a positive result in favour
of the intervention; however the open-label nature of the RCT
may have had an impact on this. Although the Research
Physiotherapist did encourage all patients following random-
ization, it was inevitable that patients allocated TBM were
disappointed. They did not have the novelty of a new
breathing mode and, in retrospect, it was probably not
surprising that adherence levels waned in the TBM group.
Similarly this open-label study design may be criticized given
that some technique training was required for the new
breathing mode, however this reflects the real life situation
and we did not feel it appropriate to provide training for a
breathing mode that the TBM group would not use.
The CF patient demonstrating the largest reduction in
treatment time was a 15 year old with Aspergers Syndrome.
Using TIM, average treatment times reduced from 9.6 to 3
minutes. Parents reported this was a result of the direct feedback
through the vibrating mouthpiece, which enabled the patient to
focus on the breathing pattern.Appendix A. Study schedule
Scre
Written informed consent ✓
Demographic information ✓
Recent medical history ✓
Medication ✓
Physical examination ✓
Pulmonary function tests ✓
Sputum sample/ cough swab ✓
Issue new chamber set/mesh plate ✓
Breathing monitor training ✓
Adverse events
Download AAD ✓
Randomisation
Issue TIM mouthpiece and teach use (If randomised to TIM)
Administer test dose Colistin via TIM (If randomised to TIM)
Offer TIM to patients randomised to TBM in study and teach use
Patient preference questionnaire (If randomised to TIM)We have previously reported on variability in treatment
times between individuals.[5] In children, this relates to some
degree on age and tidal volume. Adaptive aerosol delivery
requires active participation from the patient and the device will
not deliver aerosol unless the patient is breathing in a steady
and regular manner. For some patients, this may lead to longer
treatment times if they use the device in an erratic manner, for
example if distracted. However, the volume of drug delivered
to the lower airways does not vary significantly as the device
will only deliver during appropriate inspiratory cycles.
These results have had a direct impact on our practice. We
now advocate TIM for all patients on chronic suppressive
therapy and also for patients with a new growth of
Pseudomonas aeruginosa when we are attempting eradication.
Reducing treatment times is a major benefit to patients and their
families. Longer-term studies are needed to determine if these
improvements in treatment times can be maintained.
This is a new era of aerosol delivery and novel advances in
medical devices need to be monitored and assessed rigorously,
[14] particularly as new and potentially expensive therapies
emerge from translational studies. [14] Electronic data capture
enables CF teams to work in an open partnership with patients
to achieve the common goals of improving drug delivery and
reducing patient burden.
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TIM study.
Patient preference survey.
Please tick one answer for each statement.
1. My child found the TIM mouthpiece very easy to understand
Completely AgreeAppendix C. Consort Flow d
treatment allocationsAgreeiagram of enrollmeNeither agree nor disagreent andDisagree Completely disagree
2. My child found the TIM mouthpiece very easy to use
Completely Agree Agree Neither agree nor disagree Disagree Completely disagree
3. My child was able to use the TIM mouthpiece straight away
Completely Agree Agree Neither agree nor disagree Disagree Completely disagree
4. My child took several days to get used to the TIM mouthpiece
Completely Agree Agree Neither agree nor disagree Disagree Completely disagree
5. My child never got used to the TIM mouthpiece
Completely Agree Agree Neither agree nor disagree Disagree Completely disagree
6. My child prefers the TIM mouthpiece to the standard mouthpiece
Completely Agree Agree Neither agree nor disagree Disagree Completely disagreeReferences
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